BridgeBio Strengthens Board Commitment with Major Equity Grant to Director Scott

(Neutral)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma Director Randal W. Scott reported significant equity compensation grants on June 20, 2025. The transactions include:

6,589 Restricted Stock Units (RSUs) granted at $0, vesting over three years through June 20, 2028
8,425 Stock Options awarded with an exercise price of $41.73, vesting over three years through June 20, 2028

Following these transactions, Scott's holdings include 11,589 shares held directly and 4,000 shares held indirectly through Thinking Bench Capital LLC. Both the RSUs and stock options are subject to continued service on the board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation arrangements.

Insider Trade Summary

Net Buyer: 6,589 shares

Net Buy 3 txns

Insider Scott Randal W.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,425	$0.00	$0.00
Grant/Award	Common Stock	6,589	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 11,589 shares (Direct); Common Stock — 4,000 shares (Indirect, By Thinking Bench Capital LLC)

Footnotes (3)

F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/24/2025 - 06:54 PM

FAQ

What insider trading activity occurred at BBIO on June 20, 2025?

Director Randal W. Scott received two equity grants: 6,589 restricted stock units (RSUs) and 8,425 stock options with an exercise price of $41.73. The RSUs and stock options will vest over three years, with one-third vesting each year starting June 20, 2025, subject to continued board service.

How many BBIO shares does Director Randal Scott own after the June 2025 transaction?

Following the transaction, Randal Scott owns 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC. Additionally, he holds 8,425 stock options and 6,589 unvested RSUs.

What is the vesting schedule for BBIO's June 2025 director equity grants?

Both the RSUs and stock options granted on June 20, 2025, follow a three-year vesting schedule. One-third of the awards will vest each year after June 20, 2025, with full vesting occurring on June 20, 2028, contingent on continued service on BBIO's board of directors.

What is the exercise price of BBIO stock options granted to directors in June 2025?

The stock options were granted with an exercise price of $41.73 per share and have an expiration date of June 19, 2035.

When did BBIO Director Randal Scott report his June 2025 equity grants?

Director Randal Scott signed and reported the equity grants on June 24, 2025, within the required reporting timeline for Form 4 filings. The Form 4 was filed with the SEC on June 28, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scott Randal W.

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		A⁽¹⁾		6,589	A	$0⁽²⁾	11,589	D
Common Stock								4,000	I	By Thinking Bench Capital LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$41.73	06/20/2025		A		8,425		⁽³⁾	06/19/2035	Common Stock	8,425	$0	8,425	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Randal W. Scott, Ph.D.	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR